Ivacaftor

January 26, 2016May 12, 2016

Preschoolers With Cystic Fibrosis Yield Promising Results With Ivacaftor

News

New research published in The Lancet Respiratory Medicine journal reports that the oral drug ivacaftor is a safe therapy and has the potential to benefit young children between the ages of ... Read more

November 19, 2015

Vertex’s Cystic Fibrosis Therapy Expands to Younger Children, More Adults

Cystic Fibrosis, News

Vertex Pharmaceuticals Inc. recently confirmed that the European Commission has expanded the indication of Kalydeco® (ivacaftor) to two more groups of patients: children ages 2 to 5 with cystic fibrosis (CF) who have at least ... Read more

November 13, 2015November 13, 2015

Potential New Cystic Fibrosis Therapy, CTP-656, Begins Phase 1 Study

Cystic Fibrosis, News

Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on utilizing its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs, recently announced that it has initiated a Phase ... Read more

November 3, 2015November 24, 2015

CF Fertility Rates Research Personal for University of Alabama at Birmingham Investigator

Cystic Fibrosis, News

For Sigrid Ladores, Ph.D., a pediatric nurse practitioner and an Assistant Professor at the University of Alabama at Birmingham School of Nursing, investigating reproductive health concerns of adolescents and young ... Read more

October 12, 2015November 5, 2015

Vertex Presents Key Findings on Kalydeco, Orkambi & Experimental CF Therapies at NACFC

Cystic Fibrosis, News

A series of new updates and future development plans were recently announced by Vertex regarding its approved and candidate drugs to treat Cystic fibrosis (CF). The announcements, made at the 29th Annual ... Read more

September 23, 2015November 5, 2015

Concert Pharma Reports Phase 1 Results of Experimental CF Therapy CTP-656

Cystic Fibrosis, News

Concert Pharma, a biotechnology company utilizing deuterium chemistry to discover and develop innovative drug products that can address unmet medical needs, recently announced positive results from its Phase 1 single ascending dose study ... Read more

May 13, 2015November 5, 2015

Vertex’s New CF Drug Combo Receives Positive FDA Recommendation

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has issued a positive evaluation of ORKAMBI (lumacaftor/ivacaftor) as a recommended treatment for cystic fibrosis (CF) patients 12 years and older with two copies of the F508del mutation ... Read more

March 18, 2015November 5, 2015

Concert Pharma Starts Phase 1 Trial on Deuterated Ivacaftor for CF

Cystic Fibrosis, News

Clinical stage Concert Pharmaceuticals Inc. has initiated a phase 1 clinical study to evaluate a deuterium-modified version of ivacaftor, as a potential therapy for cystic fibrosis (CF). The company is planning on studying ... Read more

November 6, 2014November 5, 2015

Lumacaftor/Ivacaftor Drug Combo for CF Patients With Two Copies Of F508del Mutation Gains U.S., European Approval

Cystic Fibrosis, News

Vertex Pharmaceuticals Incorporated has announced its submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European ... Read more